Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (2): 228-233    DOI: 10.31083/j.ceog.2021.02.2273
Review Previous articles | Next articles
Routine blood tests in early pregnancy: their development and value in the early diagnosis of gestational diabetes mellitus
Guo-Lin Liu1, Ning-Zhi Zhang1, *()
1Fu Yang People's Hospital, No. 63 Lu Ci Street, Yingzhou District, 236000 Fuyang, Anhui Province, China
Download:  PDF(182KB)  ( 108 ) Full text   ( 16 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
With the change in China's second-child fertility policy, the numbers of older pregnant women and high-risk pregnancies have significantly increased, and the incidence of gestational diabetes mellitus (GDM) is likely to rise. GDM can cause a variety of adverse pregnancy outcomes, seriously threaten the safety of perinatal mothers and infants, and affect the long-term health of mothers and their offspring. Currently, the GDM screening period is between 24 to 28 weeks of pregnancy, but there are some shortcomings in screening at this time, since because of late diagnosis, the best time for intervention and treatment for some high-risk pregnant women may be delayed. Studies have shown that early prediction and early diagnosis of GDM is of great significance to improve pregnancy outcomes, so it is important to investigate early pregnancy prediction indexes of GDM to improve the screening efficiency for GDM and improve the management of GDM. It has been found that blood cell parameters, inflammatory factors, fat metabolism indices and liver enzyme metabolism markers have specific early predictive value for GDM. The application of these parameters combined with significant independent risk factors in the early prediction and early diagnosis of GDM will be of great value in the prevention and treatment of GDM and the prognosis of mothers and infants. This article reviews the development of routine blood test parameters during pregnancy and their value in the early diagnosis of GDM.
Key words:  Gestational diabetes mellitus      Routine blood test      Early diagnosis     
Submitted:  26 August 2020      Revised:  20 October 2020      Accepted:  06 November 2020      Published:  15 April 2021     
*Corresponding Author(s):  Ning-Zhi Zhang     E-mail:  fyniyanghe@163.com

Cite this article: 

Guo-Lin Liu, Ning-Zhi Zhang. Routine blood tests in early pregnancy: their development and value in the early diagnosis of gestational diabetes mellitus. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 228-233.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2021.02.2273     OR     https://ceog.imrpress.com/EN/Y2021/V48/I2/228

[1] C. Ji, L.J. Sun, L.T. Li, J. Ma, W.H. Ge, X. Zhao. Impact of clinical pharmacist intervention on blood glucose control and perinatal outcomes in gestational diabetes mellitus through a diabetes management system[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 645-652.
[2] H. Ueda, T. Miyamoto, Y. Tsurusaki, G. Minase, N. Matsumoto, K. Sengoku. Rapid diagnostic testing of a neonate in a family with hypertrophic cardiomyopathy[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 496-499.
[3] Hongying Zhang, Qingling Wei, Jinlan Wei, Haiyang Pang, Wenxuan Wei, Yu Sun, Mengya He, Yanling Sun. Importance of diagnosis time on pregnancy outcomes in pregnant women with pre-gestational diabetes mellitus[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 57-61.
[4] L. Yuanmei, Z. Qian, X. Fengsen, W. Yankui. Restricted gestational weight gain in overweight/obese women with gestational diabetes mellitus and pregnancy outcomes[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 763-769.
[5] Y. Huo, S.-X. Liu, L. Li, J. Feng, H.-Y. Li, G.-Y. Song. Circulating vaspin and IL-6 concentrations in second trimester pregnancy with gestational diabetes[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 211-215.
[6] J. Agah, F. Roodsarabi, A. Manzuri, M. Amirpour, A. Hosseinzadeh. Prevalence and associated risk factors of gestational diabetes mellitus in a tertiary hospital in Iran[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 85-89.
[7] H. Bagci, R. Melekoglu, M.F. Gursu, A. Akyol, F. G. Bulmus. Associations between serum levels of adiponectin and resistin and metabolic parameters in pregnant women with gestational diabetes mellitus[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 539-543.
[8] Y. Yang, B.R. Luo, M. Hu, D.M. Zhao, W.J. Jing. Association of CD36 gene single nucleotide polymorphism with gestational diabetes mellitus in Chinese Han population[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 266-271.
[9] A. Ferraiolo, C. Bordone, A. Ramone, P. Sala, F. Gorlero, C. Gustavino, R. Cordera. Universal versus risk factor screening for gestational diabetes mellitus[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(1): 53-57.
[10] A.M. Oraif, H.A. Jabar, M. Ashi, H. Al Ghanmi, A.R. Al Jarallah. Is there a relationship between maternal blood type and the incidence of gestational diabetes mellitus? A retrospective review[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(5): 755-757.
[11] N. Tokgozoglu, E. Cakar, V. Sal, E. Erdogdu, A. Namazov, I. Kahramanoglu, H. Turan. Effect of borderline glucose intolerance on fetal maternal outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(4): 562-565.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] Sandeep K. Krishnan, Norman E. Lepor. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 9 -21 .
[3] Ibrahim Sidiqi, Patrick Alexander. Current Advances in Endovascular Therapy for Infrapopliteal Artery Disease[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 36 -50 .
[4] Prakash C. Deedwania. Management of Patients With Stable Angina and Type 2 Diabetes[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 105 -113 .
[5] Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38 -46 .
[6] Sophie Mavrogeni, Fabrizio Cantini, Gerald M. Pohost. Systemic Vasculitis: An Underestimated Cause of Heart Failure—Assessment by Cardiovascular Magnetic Resonance[J]. Reviews in Cardiovascular Medicine, 2013, 14(1): 49 -55 .
[7] George L. Smith. Appropriate Use Criteria: The Gold Standard, or a Mechanism for the Derogation of Clinical Judgment?[J]. Reviews in Cardiovascular Medicine, 2011, 12(2): 105 .
[8] Dean J. Kereiakes. Coronary Small-Vessel Stenting in the Era of Drug Elution[J]. Reviews in Cardiovascular Medicine, 2004, 5(S2): 34 -45 .
[9] Steven V. Edelman. The Role of the Thiazolidinediones in the Practical Management of Patients With Type 2 Diabetes and Cardiovascular Risk Factors[J]. Reviews in Cardiovascular Medicine, 2003, 4(S6): 29 -37 .
[10] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .